Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

What is Cancer?

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...

What is Cancer?

What is Cancer?

Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026

Same author

Untargeted metabolomics and lipidomics to study autophagy induction in mouse embryonic fibroblasts.

Analytical and bioanalytical chemistry·2025

Same author

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.

Journal of medicinal chemistry·2025

Same author

Role of FAPI PET/CT in cancer of unknown primary (CUP): A systematic review.

European journal of radiology·2025

Same author

Comparison of inter- and intraobserver agreement between [<sup>18</sup>F]AlF-NOTA-octreotide and [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT.

EJNMMI reports·2025

Same author

Clinical impact of using [<sup>18</sup>F]AlF-NOTA-octreotide PET/CT instead of [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.

Journal of neuroendocrinology·2024

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Sarcoma.

Sarah Ceyssens¹, Sigrid Stroobants

¹Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium. sarah.ceyssens@usa.be

Methods in Molecular Biology (Clifton, N.J.)

|February 19, 2011

Summary

This study reviews 18F-FDG PET imaging for diagnosing and staging soft tissue sarcomas. It highlights the role of imaging in guiding biopsies and assessing treatment response for these connective tissue malignancies.

Area of Science:

Oncology
Radiology
Medical Imaging

Background:

Sarcomas are rare connective tissue malignancies requiring accurate diagnosis and staging.
Current imaging modalities aid in differentiating benign from malignant masses and guiding biopsies.
Soft tissue sarcomas present unique challenges due to their size and heterogeneity.

Purpose of the Study:

To provide an overview of 18F-FDG PET imaging in the management of sarcomas.
To discuss the strengths and limitations of 18F-FDG PET in clinical settings.
To explore the utility of imaging in guiding biopsies for suspected sarcomas.

Main Methods:

Review of the application of 18F-FDG PET in sarcoma diagnosis and staging.
Evaluation of imaging's role alongside pathology for comprehensive patient assessment.

More Related Videos

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Related Experiment Videos

Last Updated: Jun 4, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Discussion of imaging in screening for metastases and monitoring treatment response.

Main Results:

18F-FDG PET demonstrates utility in identifying malignant potential and guiding biopsies.
Imaging is crucial for accurate staging, assessing local extent, and detecting recurrence.
The modality aids in evaluating treatment efficacy and identifying occult metastatic disease.

Conclusions:

18F-FDG PET is a valuable tool in the multidisciplinary approach to sarcoma management.
Imaging supports accurate staging, treatment monitoring, and recurrence detection.
Understanding the strengths and limitations of 18F-FDG PET is essential for optimal use.